Incyte Nears $2B Star Therapeutics Deal

What happened

Incyte is reportedly nearing a $2 billion acquisition of blood disorder biotech Star Therapeutics, according to the Financial Times. The deal, if completed, would add Star's pipeline to Incyte's portfolio as it seeks to diversify ahead of the 2028 Jakafi patent cliff. However, the acquisition comes at a time when Incyte's stock already trades at a rich ~45x EV/EBITDA, reflecting high expectations for Opzelura and oncology ramp. The $2 billion price tag would consume a significant portion of Incyte's $1.7 billion cash position, raising capital allocation and integration concerns. While the deal could bolster Incyte's blood disorder franchise, it introduces additional execution risk and may signal management's urgency to fill the looming revenue gap.

Implication

Over a 12-18 month horizon, Incyte must prove that Star's assets can contribute materially pre-2028 to offset Jakafi erosion. If the deal dilutes focus or fails to deliver returns, it could exacerbate the valuation reset risk already embedded in the sell thesis. Conversely, a well-priced acquisition with a promising late-stage asset could improve the long-term diversification story, but this is not the base case given management's uneven M&A track record.

Thesis delta

The acquisition news does not alter the core sell thesis, which already flagged high valuation and dependency on Opzelura and tafasitamab. However, it introduces a new capital allocation risk that likely increases the probability of value destruction, making the bear case more tangible. The deal's success hinges on Star's pipeline execution—a high bar given Incyte's own struggles to scale non-Jakafi revenues.